Transformation of revenue sources is the main positives. They earned slightly less but this is despite the huge difference in contribution from the US generic portfolio. The generic portfolio is where margins are less, competition is high and therefore if the rest keep going up, there is a good chance that Mayne will establish reliable income sources that will grow at a reasonable rate of 10% per annum.
- Forums
- ASX - By Stock
- MYX
- Ann: 2021 Full Year Media Release
MYX
mayne pharma group limited
Add to My Watchlist
0.40%
!
$5.02

Ann: 2021 Full Year Media Release, page-4
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$5.02 |
Change
0.020(0.40%) |
Mkt cap ! $407.8M |
Open | High | Low | Value | Volume |
$5.05 | $5.09 | $4.96 | $774.1K | 154.0K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 3317 | $4.99 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$5.04 | 1291 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 1317 | 4.990 |
1 | 1000 | 4.980 |
1 | 1000 | 4.960 |
1 | 1291 | 4.950 |
1 | 870 | 4.940 |
Price($) | Vol. | No. |
---|---|---|
5.040 | 1291 | 1 |
5.060 | 6210 | 4 |
5.080 | 1291 | 1 |
5.090 | 1100 | 2 |
5.100 | 1875 | 2 |
Last trade - 16.10pm 25/06/2025 (20 minute delay) ? |
Featured News
MYX (ASX) Chart |